Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication

被引:0
作者
Spadaccini, A [1 ]
De Fanis, C
Sciampa, G
Russo, L
Silla, M
Pantaleone, U
Di Virgilio, M
Pizzicanella, G
机构
[1] Presidio Osped, Div Gastroenterol & Endoscopia Digest, Dept Gastroenterol & Digest Endoscopy Dept, I-66054 Vasto, CH, Italy
[2] Presidio Osped, Dept Anat Pathol, I-66054 Vasto, CH, Italy
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: A-combination of an antisecretory agent with two antibiotics is considered the 'gold standard' for Helicobacter pylori eradication. Objectives: To compare the eradication rates and the safety profile of two short-term triple therapies containing lansoprazole (L) or ranitidine bismuth citrate (RBC) as antisecretory agents. Methods: One hundred and twelve H pylori-positive patients either with peptic ulcer (56 duodenal ulcers: 25 active and 31 with a history of ulcer; 13 gastric ulcers: nine active and four with a history of ulcer) or gastritis (43) were included in an open, randomized, controlled trial. a pylori infection was initially detected by CLO-test and histology on antral and corpus biopsies. H. pylori-positive patients were randomized to receive L plus clarithromycin (C) 250 mg b.d. plus tinidazole (T) 500 mg b.d. (LCT) or RBC plus C 250 mg b,d. and T 500 mg b.d. for 7 days (RbcCT). L or RBC were administered for a further 3 weeks in patients with active peptic ulcers; A second endoscopy was performed at least 6 weeks after the end of therapy for the assessment of H. pylori infection by CLO-test and histology. Eradication-was assumed if all the tests were negative for H. pylori. Results: Forty-eight patients in the LCT group and 45 in the RbcCT group were assessed for H. pylori eradication. The eradication rates, according to intention-to-treat (ITT) and per protocol (PP) analyses were, respectively, 76.8% and 89.5% for the LCT group, and 73.2% and 91.1% for the RbcCT group. No statistically significant difference in eradication rates was found between the two groups by Mantel-Haenszel test, All peptic ulcers were healed. In patients in whom H. pylori had been eradicated, the severity of gastritis was significantly reduced. Side-effects were rare. One patient in the LCT group and two in the RbcCT group were withdrawn because of adverse events. Conclusion: Short-term triple therapy with either lansoprazole or RBC is equally effective and well tolerated.
引用
收藏
页码:997 / 1001
页数:5
相关论文
共 13 条
  • [1] SHORT-TERM LOW-DOSE TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER-PYLORI
    BAZZOLI, F
    ZAGARI, RM
    FOSSI, S
    POZZATO, P
    ALAMPI, G
    SIMONI, P
    SOTTILI, S
    RODA, A
    RODA, E
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1994, 6 (09) : 773 - 777
  • [2] Cannizzaro O, 1997, GUT, V41, pA206
  • [3] Catalano F, 1997, GUT, V41, pA213
  • [4] Gudjonsson H, 1997, GUT, V41, pA99
  • [5] HETZEL DJ, 1997, GUT, V41, pP742
  • [6] HOPKINS RJ, 1997, GASTROENTEROLOGY S6, V113, P126
  • [7] Malfertheiner P, 1997, GUT, V41, P8
  • [8] Marchi S, 1997, GUT, V41, pA206
  • [9] Clarithromycin dual therapy regimens for eradication of Helicobacter pylori: A review
    Pipkin, GA
    Dixon, JS
    Williamson, R
    Wood, JR
    [J]. HELICOBACTER, 1997, 2 (04) : 159 - 171
  • [10] A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics
    Savarino, V
    Mansi, C
    Mele, MR
    Bisso, G
    Mela, GS
    Saggioro, A
    Caroli, M
    Vigneri, S
    Termini, R
    Olivieri, A
    Tosatto, R
    Celle, G
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (04) : 699 - 703